Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for weight ...

Emrelis wins FDA approval, marking ABBV's first lung cancer drug and strengthening its oncology reach into solid tumors.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

"We recommend that any patients experiencing side effects while taking GLP-1 receptor agonists including Wegovy® (semaglutide ...

An Ozempic warning has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA) for any women taking ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Ability Biotherapeutics, a biotechnology leader focused on developing next-generation antibody therapies, is pleased to announce the appointment of Angèle Maki, PhD to its Board of Directors. Dr. Maki ...

Cambridge UK and Tokyo biopharma business Nxera Pharma has hauled in $15 million after partner Neurocrine Biosciences dosed the first patient in its Phase 3 registrational programme of NBI-1117568 ...

Diabetes care startup Omada Health went public Friday 14 years after its founding. Here's what its major investors' stakes ...